Status:

COMPLETED

DaVita Assessment of Nutritional Supplement Effects (DANSE)

Lead Sponsor:

Davita Clinical Research

Collaborating Sponsors:

Abbott Nutrition

Conditions:

Malnutrition

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

This is a Phase IV randomized controlled study assessing the effectiveness of a commercially available nutritional supplement on malnourished prevalent hemodialysis patients. Patients will be randomiz...

Eligibility Criteria

Inclusion

  • Patient is at least 18 years of age
  • Patient has been on hemodialysis \>6 months at the time of study entry
  • Patient dialyzes three times a week
  • Patient agrees to try ONS for the 6 month study period.
  • Patient has demonstrated an albumin \<3.5 g/dL on last available lab drawn in dialysis facility
  • Patient is adequately dialyzed with a Kt/V \> 1.4 at the most recent lab draw
  • Patient is capable of reading and comprehending Informed Consent Form and provides written informed consent

Exclusion

  • Peritoneal dialysis
  • Dysphagia
  • Aspiration risk
  • Difficulty swallowing
  • History of symptomatic intolerance to food or liquid consumption during dialysis treatments
  • Terminal illnesses with life expectancy \<6 months, e.g. stage IV cancer or full blown AIDS
  • Concurrent appetite stimulants
  • Use of IDPN in last 3 months
  • Inability to follow and to comply with the instructions and guidelines
  • Severe liver disease defined as most recent SGOT \> 78
  • Active malignancy (other than skin)
  • Major surgery within previous 6 months or anticipated during the 90-day study period
  • Females who are pregnant or are breast-feeding
  • Considered clinically unstable by the treating nephrologists
  • Noncompliance with dialysis treatments ( Missed \> 2 treatments in prior month due to noncompliance)
  • Extended or frequent hospitalizations defined as hospitalization of longer than 15 days with discharge within the last 30 days or greater than 3 admissions within the last 30 days
  • Regular supplement use defined as consumption of \> 7 servings of a commercially available kcal/ protein supplement in the prior month
  • Any clinically significant medical disease or condition that, in the investigator's opinion, may interfere with protocol adherence or a patient's ability to give informed consent

Key Trial Info

Start Date :

April 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

160 Patients enrolled

Trial Details

Trial ID

NCT00895401

Start Date

April 1 2009

Last Update

February 8 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

DaVita

Irvine, California, United States, 92618